A5013484343- Myasthenia Gravis and Thymoma
- Peripheral Neuropathies and Disorders
- Antifungal resistance and susceptibility
- Parkinson's Disease and Spinal Disorders
- Cancer Treatment and Pharmacology
- Thyroid and Parathyroid Surgery
- Autoimmune Neurological Disorders and Treatments
- Congenital Heart Disease Studies
- RNA regulation and disease
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Pituitary Gland Disorders and Treatments
- S100 Proteins and Annexins
- Alzheimer's disease research and treatments
- Neuroscience and Neuropharmacology Research
- Congenital Diaphragmatic Hernia Studies
- Pharmacological Effects and Toxicity Studies
- Prosthetics and Rehabilitation Robotics
- Central Venous Catheters and Hemodialysis
- Multiple Sclerosis Research Studies
- Vascular anomalies and interventions
- Mechanical Circulatory Support Devices
- Viral Infections and Immunology Research
- Balance, Gait, and Falls Prevention
- Parkinson's Disease Mechanisms and Treatments
- Cellular Mechanics and Interactions
Chiba University
2014-2024
Chiba Hospital
2014-2024
Kubota (Japan)
2024
Toho University Ohashi Medical Center
2024
Toho University
2024
Tokyo Medical University
2024
Keio University
2024
Fukuoka Children's Hospital and Medical Center for Infectious Diseases
2024
Kyushu University
2017-2023
Oita Prefectural Hospital
2020-2023
Background Early fast-acting treatment (EFT) is the aggressive use of therapies such as plasmapheresis, intravenous immunoglobulin and/or high-dose methylprednisolone (IVMP) from early phases treatment. EFT reportedly beneficial for achievement minimal manifestations (MM) or better status with ≤5 mg/day prednisolone (MM5mg), a practical therapeutic target myasthenia gravis (MG). Objective The current study aimed to clarify which specific regimen efficacious and patient characteristics that...
Efgartigimod, which has been well tolerated and efficacious in individuals with generalized myasthenia gravis (MG), is available Japan not only for the treatment of anti-acetylcholine receptor-positive (AChR+) but also anti-muscle-specific receptor tyrosine kinase (MuSK+) seronegative MG. We report details use efgartigimod MG clinical practice Japan.
Abstract Objective Eculizumab and ravulizumab are complement protein C5 inhibitors, showing efficacy tolerability for patients with anti‐acetylcholine receptor‐positive (AChR+) generalized myasthenia gravis (gMG) in phase 3 clinical trials subsequent analyses. The purpose of the present study was to evaluate significance eculizumab switching refractory AChR+ gMG real‐world experience. Methods Among database Japan MG registry survey 2021, we studied who received eculizumab. We also evaluated...
Summary Myasthenia gravis (MG) is an autoimmune-mediated inflammatory disease of the neuromuscular junction. Previous studies animal MG models have suggested important roles cytokines in pathogenesis, but adequate on human are lacking. Using a multiplex suspension array system, we measured serum levels 27 cytokines/chemokines 47 anti-acetylcholine receptor antibody-positive patients with and 20 normal controls (NC) to investigate contribution toward pathogenesis. Correlations between...
Objectives To clarify the social disadvantages associated with myasthenia gravis (MG) and examine associations its disease treatment. Design Cross-sectional study. Setting participants We evaluated 917 consecutive cases of established MG seen at 13 neurological centres in Japan over a short duration. Outcome measures All patients completed questionnaire on resulting from treatment 15-item MG-specific quality life scale study entry. Clinical severity worst condition was graded according to...
ABSTRACT Introduction In this study we sought to clarify the effects of early fast‐acting treatment (EFT) strategies on time course for achieving target in generalized myasthenia gravis (MG). Methods This retrospective 923 consecutive MG patients analyzed 688 who had received immunotherapy during disease course. The first achieve minimal manifestations (MM) or better while receiving prednisolone at ≤5 mg/day ≥6 months (MM‐or‐better‐5mg) up 120 after starting was compared between EFT and...
Abstract Myasthenia gravis (MG) is an autoimmunological inflammatory disorder of the neuromuscular junction. Inflammation could be a key player for understanding pathogenesis MG. We measured serum levels 24 cytokines in 43 patients with anti-acetylcholine receptor antibody-positive MG and 25 healthy controls. In MG, proliferation-inducing ligand (APRIL), IL-19, IL-20, IL-28A IL-35 were significantly increased as compared controls (p < 0.05). Among them, decreased after treatment clinical...
Eculizumab is a humanized monoclonal antibody that targets complement protein C5 and inhibits terminal complement-mediated damage at the neuromuscular junction. Recently, REGAIN study showed eculizumab was effective well tolerated in patients with anti-acetylcholine receptor antibody-positive refractory generalized myasthenia gravis (gMG). However, there no consensus regarding which kind of gMG are selected to preferentially receive eculizumab.Between January December 2018, we followed 1388...
Myasthenia gravis (MG) is an autoimmune disease mostly caused by autoantibodies against acetylcholine receptor associated with thymus abnormalities. Thymectomy has been proven to be efficacious treatment for patients MG, but postoperative myasthenic crisis often occurs and a major complication. We aimed develop validate simple scoring system based on clinical characteristics in the preoperative status predict risk of crisis.We studied 393 MG who underwent thymectomy at 6 tertiary centers...
Abstract Objectives Recently, the EUROIMMUN anti‐acetylcholine receptor antibody (AChR Ab) enzyme‐linked immunosorbent assay (ELISA) became commercially available in Japan, but its clinical performance has not been comprehensively researched. This is first diagnostic evaluation of AChR Ab ELISA carried out Japanese population, including stratification myasthenia gravis (MG) patients according to length treatment. Methods Concentrations sera from clinically confirmed MG ( n = 85) and non‐MG...
Anti-ryanodine receptor (RyR) antibodies were measured in sera from 33 myasthenia gravis (MG) patients using three peptides the human RyR1 sequence, two C-terminal included functional calcium release channel, and an N-terminal peptide implicated ion-conduction. Antibodies more frequently positive against peptides, particularly thymoma-associated MG. In a preliminary open trial with FK506, immunosuppressant enhancer of RyR-related sarcoplasmic release, authors observed sustained benefits...
Background and purpose A single, oral dose of 3 mg/day tacrolimus, approved for myasthenia gravis ( MG ) treatment in Japan, was shown to reduce steroid anti‐acetylcholine receptor AC hR) antibody titers as well improve symptoms. However, no studies have investigated the association between tacrolimus concentration its clinical efficacy . In this study, we aimed determine optimal treatment. Methods The trough 51 patients with (positive anti‐ hR antibody, n = 48; negative anti‐muscle‐specific...
We have previously reported using two-step cluster analysis to classify myasthenia gravis (MG) patients into the following five subtypes: ocular MG; thymoma-associated MG with thymic hyperplasia; anti-acetylcholine receptor antibody (AChR-Ab)-negative and AChR-Ab-positive without abnormalities. The objectives of present study were examine reproducibility this five-subtype classification a new data set identify additional characteristics these subtypes, particularly in regard response...
Abstract The primary purpose of the Japanese myasthenia gravis registry (JAMG‐R) has been to research and promote high‐quality medical care for MG patients in Japan. We reviewed findings surveys performed by JAMG‐R over an ~10‐y period. first goal favorable quality life (QOL) is a status minimal manifestations (MM) or better with oral prednisolone (PSL) dose 5 mg/d less (MM‐5 mg). E arly aggressive use nonoral f ast‐acting t reatment together low‐dose PSL (the “EFT strategy”) recommended...
Non-motor symptoms in myasthenia gravis (MG) are rarely confirmed. Although there some small cohort studies, a large-systemic survey has not yet been performed.
Objective To investigate the association between changes in anti-acetylcholine receptor antibody (AChR Ab) levels induced by immunosuppressive treatment and myasthenia gravis (MG) prognosis at 1-year post-treatment patients with MG. Methods We included 53 consecutive AChR Ab-positive MG whose Ab were remeasured within 100 days of initiating (median remeasuring time post-treatment: 71 (55–84) days). The level reduction rate (RR-AChRAb, %/day) adjusted for initiation, remeasurement was...